Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

A/Prof Ron Dick

Why is LDL control important?

Prof Carol Wham

Malnutrition and frailty in older adults - The importance of screening and early intervention

Prof Andrew Sindone

Heart failure and obesity - Which do we manage first?

Brett Lee

The social media ban - Practical preparation for children and family

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

25 November 2025

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD